Get started
Author

Thomas Brevig

Observed names: Brevig T, T Brevig, T. Brevig
OpenAlex ID: A5090284030
Risk factors for migraine disease progression: a narrative review for a patient-centered approach
2023 · Richard B. Lipton, Dawn C. Buse, et al. · Journal of Neurology · 113
PDF
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2
2020 · Hans‐Christoph Diener, Michael J. Marmura, et al. · Headache The Journal of Head and Face Pain · 102
PDF
Patient-centered assessment of cognitive symptoms of depression
2013 · Sheri E. Fehnel, Barbara H. Forsyth, et al. · CNS Spectrums · 94
PDF
Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study
2018 · Cecilia Brain, Steven Kymes, et al. · BMC Psychiatry · 70
PDF
Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists
2019 · Christoph U. Correll, Thomas Brevig, et al. · BMC Psychiatry · 55
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
2021 · Timothy R. Smith, Egilius L. H. Spierings, et al. · The Journal of Headache and Pain · 46
PDF
Psychometric Validation of Perceived Deficits Questionnaire – Depression (PDQ-D) in Patients with Major Depressive Disorder (MDD)
2013 · R.W. Lam, D. Saragoussi, et al. · Value in Health · 45
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
2021 · Michael J. Marmura, Hans‐Christoph Diener, et al. · Headache The Journal of Head and Face Pain · 42
PDF
Patient preference for early onset of efficacy of preventive migraine treatments
2022 · Jessica Ailani, Paul Winner, et al. · Headache The Journal of Head and Face Pain · 19
Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists
2019 · Christoph U Correll, Thomas Brevig, et al. · Neuropsychiatric Disease and Treatment · 17
PDF
Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized PROMISE ‐2 trial
2023 · Amaal J. Starling, Robert P. Cowan, et al. · Headache The Journal of Head and Face Pain · 16
PDF
Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
2022 · Dawn C. Buse, Paul K. Winner, et al. · The Journal of Headache and Pain · 14
PDF
The Transdiagnostic Global Impression - Psychopathology scale (TGI-P): Initial development of a novel transdiagnostic tool for assessing, tracking, and visualising psychiatric symptom severity in everyday practice
2024 · Christoph U. Correll, Zsófia B. Dombi, et al. · European Neuropsychopharmacology · 10
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
2022 · Robert P. Cowan, Michael J. Marmura, et al. · The Journal of Headache and Pain · 6
PDF
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
2022 · Richard B. Lipton, Larry Charleston, et al. · The Journal of Headache and Pain · 6
PDF
Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains
2025 · Agota Barabassy, Réka Csehi, et al. · Pharmaceuticals · 4
PDF
Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression – Psychopathology scale for patients and informants
2025 · Roger S. McIntyre, Zsofia Borbala Dombi, et al. · European Psychiatry · 2
PDF
Treatment with Eptinezumab for Migraine Prevention in People with Chronic Migraine and Medication-Overuse Headache: A Plain Language Summary
2023 · Amaal J Starling, Melissa Kolbet, et al. · Pain Management · 1
PDF
Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
2021 · Timothy R. Smith, Egilius L. H. Spierings, et al. · The Journal of Headache and Pain · 1
PDF
Patient Preference for Early Onset of Efficacy in Migraine Prevention (1749)
2021 · Paul Winner, Agathe Le Lay, et al. · Neurology · 1
Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men
2026 · Thomas Brevig, Borbála Szepes, et al. · Diabetes Obesity and Metabolism
PDF
Life engagement improvements with cariprazine in schizophrenia: a post-hoc analysis of PANSS data from short-term studies
2026 · Réka Csehi, Péter Szabó, et al. · The International Journal of Neuropsychopharmacology
Life engagement improvements with cariprazine in schizophrenia: a post hoc analysis of PANSS data from short-term studies
2026 · Á. Barabássy, P. Szabó, et al. · Neuroscience Applied
Keeping the body in mind: Development of the Transdiagnostic Global Impression–Somatic Symptoms and Signs (TGI-3S) scale
2026 · Roger S. McIntyre, Agota Barabassy, et al. · European Psychiatry
PDF
Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression – Psychopathology scale for patients and informants – ADDENDUM
2025 · Roger S. McIntyre, Zsofia Borbala Dombi, et al. · European Psychiatry
PDF
Works count: 36
Citation count: 664
H-index: 12
I10-index: 13
Year
Topic
Type